Guangdong Transtek Medical Electronics Co. Ltd. Class A

Guangdong Transtek Medical Electronics Co. Ltd. Class A

SSZSE:300562
12.08
CNY
-0.22
(-1.79%)
0.45EPS
31.96P/E
3.23BMarket Cap
Apr 29Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.84
3.33
4.46
5.26
4.37
4.2
4.55
7.05
8.21
4.94
4.11
4.53
4.53
4.8
Basic EPS, GAAP
0.26
0.33
0.36
0.55
0.09
0.13
0.16
0.37
0.04
-0.15
0.16
0.28
0.38
0.46
Free Cash Flow per Basic Share
0.01
0.26
0.02
0.14
-0.42
0.33
0.22
-0.11
-0.31
0.29
0.28
0.42
0.64
- -
Dividend per Share
0.02
0.03
0.1
0.06
0.06
0.03
0.02
0.03
0.2
0.02
0.03
0.3
0.29
0.13
Book Value per Share
0.91
1.33
1.59
2.68
2.71
2.84
2.99
3.43
4.91
4.71
4.8
4.58
4.69
5.08
Tangible Book Value per Share
0.64
1.08
1.34
2.5
2.41
2.49
2.65
2.96
4.47
4.27
4.41
4.25
4.43
4.85
Basic Weighted Avg Shares
134
137
141
146
198
185
194
190
222
216
215
217
218
219
Sales/Revenue/Turnover
381
456
629
771
867
775
884
1,337
1,821
1,065
884
984
986
1,049
Operating Margin (%)
9.6
10.63
7.09
9.81
1.68
3.64
3.78
7.28
0.91
-1.52
2.52
6.2
10.74
13.58
Depreciation Expense
3
3
4
6
9
12
14
15
24
31
29
27
26
- -
Net Income, GAAP
35
45
50
81
18
24
31
70
9
-32
34
61
82
101
Effective Tax Rate (%)
15.6
14.15
14.62
13.77
32.11
22.67
18.87
5.61
- -
- -
5.78
3.14
4.83
7.24
Profit Margin (%)
9.23
9.95
7.98
10.45
2.06
3.1
3.52
5.25
0.49
-3.04
3.89
6.24
8.31
9.61
Working Capital
57
108
119
357
240
247
226
209
480
484
510
530
604
654
LT Debt
- -
- -
- -
3
- -
- -
- -
20
13
5
7
4
- -
2
Total Equity
122
189
225
506
514
538
568
655
1,047
999
1,024
977
1,003
1,090
Return on Invested Capital (%)
28.2
26.41
19.01
19.37
1.57
3.73
5.32
10.47
- -
- -
2.89
4.98
7.56
8.9
Return on Capital (%)
33.01
29.16
24.28
19.69
3.52
4.77
5.77
11
- -
- -
3.61
6
7.74
9.01
Return on Common Equity (%)
32.89
29.16
24.28
22.04
3.5
4.58
5.62
11.49
1.04
-3.13
3.35
6.03
8.12
9.51

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
49
62
39
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
219
219
219
Market Capitalization
2,818
2,953
3,229

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
996
996
1,026
Cash, Cash Equivalents & STI
741
739
730
Accounts Receivable, Net
178
151
160
Inventories
58
86
111
Total Current Liabilities
352
343
372
Payables & Accruals
- -
- -
- -
ST Debt
49
62
39
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.83%
11.17%
2.72%
Free Cash Flow
0.28%
25.34%
52.27%
Net Income, GAAP
-47.38%
-129.25%
33.63%
Sales/Revenue/Turnover
7.89%
-2.15%
0.23%
Total Cash Common Dividend
178.26%
368.38%
-2.95%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
249
250
258
228
984
2025
273
248
- -
229
986
2026
284
251
286
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
0.1
0.07
0.05
0.28
2025
0.11
0.09
- -
0.07
0.38
2026
0.15
0.13
0.11
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.15
0.15
- -
0.3
2025
- -
0.15
- -
- -
0.29
2026
- -
0.13
- -
- -
- -

Company Description

CEO
Zhi Gang Pan
Full Time Employees
1,089
Sector
Health technology
Industry
Medical specialties
Address
East Zone, Fiyta Technology Building Zhongshan GD China 528437
IPO Date
Nov 16, 2016
Business
Guangdong Transtek Medical Electronics Co., Ltd (300562.SZ) develops and manufactures medical electronic devices focused on blood pressure monitoring and healthcare solutions. The company offers upper arm blood pressure monitors, wrist blood pressure monitors, body composition analyzers, and related accessories under brands such as iHealth and Transtek; it also provides blood pressure management software platforms and telemedicine services. Transtek operates primarily in the consumer health and medical device segments, targeting individual consumers, healthcare providers, and partners worldwide, with manufacturing and sales in China and exports to North America, Europe, Asia-Pacific, and other regions; founded in 2002, it is headquartered in Dongguan, Guangdong Province, China. In recent developments, Transtek expanded its product portfolio with new smart blood pressure monitors integrated with AI algorithms for enhanced accuracy and launched iHealth-branded devices tailored for home use in international markets during 2024. The company formed strategic partnerships with global distributors, including expansions in the U.S. and European telehealth sectors, and completed a funding round aimed at R&D in wearable health tech in late 2024. Additionally, Transtek reorganized its international sales structure to support growth in emerging markets and announced a new production facility in 2025 to increase capacity for body fat scale and blood pressure products.